אסטוניה -
אסטונית -
Adama
mirador® forte
adama - emulsioonikontsentraat - asoksüstrobiin + tebukonasool - fungitsiidid
אסטוניה -
אסטונית -
Adama
mirador® xtra
adama - suspensioonikontsentraat - asoksüstrobiin + tsüprokonasool - fungitsiidid
אסטוניה -
אסטונית -
Adama
mistral® 700 wg
adama - vees dispergeeruvad graanulid - metribusiin - herbitsiidid
אסטוניה -
אסטונית -
Adama
seedron®
adama - suspensioonikontsentraat - fludioksoniil + tebukonasool - muud tooted
אסטוניה -
אסטונית -
Adama
sultan® super
adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
elonva
n.v. organon - korifollitropiin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - suguhormoonid ja genitaalsüsteemi, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
renagel
sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - kõik muud ravitoimingud - renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
gamifant
swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).
האיחוד האירופי -
אסטונית -
EMA (European Medicines Agency)
evrysdi
roche registration gmbh - risdiplam - lihase atroofia, spinaalne - muud lihas-skeleti süsteemi häirete ravimid - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.